{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:36:59Z","timestamp":1790462219731,"version":"4.1.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1001\/jamaophthalmol.2018.7089","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T12:41:39Z","timestamp":1550148099000},"page":"343","source":"Crossref","is-referenced-by-count":10,"title":["The Argument for Sterile Loading of All Intravitreal Injections and the Benefit of Replicated Results"],"prefix":"10.1001","volume":"137","author":[{"given":"Brian L.","family":"VanderBeek","sequence":"first","affiliation":[{"name":"Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia"},{"name":"Leonard Davis Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"evp180007r1","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1001\/jamaophthalmol.2018.3939","article-title":"Association of acute endophthalmitis with intravitreal injections of corticosteroids or anti\u2013vascular growth factor agents in a nationwide study in France.","volume":"136","author":"Baudin","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"evp180007r2","article-title":"Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab","author":"Bavinger","journal-title":"Retina"},{"issue":"10","key":"evp180007r6","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/jamaophthalmol.2015.2556","article-title":"Association of compounded bevacizumab with postinjection endophthalmitis.","volume":"133","author":"VanderBeek","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"evp180007r7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/IAE.0000000000000399","article-title":"Intravitreal injection technique and monitoring: updated guidelines of an expert panel.","volume":"34","author":"Avery","year":"2014","journal-title":"Retina"},{"key":"evp180007r8","doi-asserted-by":"publisher","first-page":"xx","DOI":"10.1016\/j.ajo.2017.11.021","article-title":"Endophthalmitis: then and now.","volume":"187","author":"Relhan","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"evp180007r9","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.ophtha.2015.07.005","article-title":"The association between intravitreal steroids and post-injection endophthalmitis rates.","volume":"122","author":"VanderBeek","year":"2015","journal-title":"Ophthalmology"},{"issue":"5","key":"evp180007r10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/archopht.123.5.649","article-title":"Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent response to treatment.","volume":"123","author":"Bucher","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"evp180007r3","unstructured":"Corbett-CorrenJ. FDA warns on eye infections with repackaged Avastin. https:\/\/www.wsj.com\/articles\/SB10001424053111904716604576542233203196792. Published August 31, 2011. Accessed January 3, 2019."},{"key":"evp180007r4","unstructured":"Office of Communications, Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration. Mixing, diluting, or repackaging biological products outside the scope of an approved biologics license application. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm434176.pdf. Published January 2018. Accessed January 3, 2019."},{"key":"evp180007r5","unstructured":"EmersonG. American Society of Retina Specialists: take action to preserve access to Avastin. https:\/\/www.asrs.org\/advocacy-practice\/access-to-safe-compounded-agents. Published 2015. Accessed January 2, 2019."}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaophthalmology\/article-pdf\/137\/4\/343\/17459421\/jamaophthalmology_vanderbeek_2019_vp_180007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T22:28:56Z","timestamp":1555021736000},"score":1,"resource":{"primary":{"URL":"http:\/\/archopht.jamanetwork.com\/article.aspx?doi=10.1001\/jamaophthalmol.2018.7089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.7089","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,1]]}}}